Adagrasib is a KRAS G12C mutation inhibitor that has been studied for the past several years in patients with these mutations. This drug is similar to Sotorasib, which is FDA approved and available for use. Adagrasib appears to have good efficacy in a subset of patients with non-small cell lung cancer with the G12C mutation in KRAS as shown by data from a phase 2 study.
In parallel, other results obtained in this research show that many of the patients diagnosed with this type of pathology, who also have brain metastases, had a good and long-lasting response to therapy in the brain.
